The White House withdrew the nomination of Dr. Heidi Overton to run the Food and Drug Administration, abandoning President Trump's pick to lead the agency that regulates roughly $3 trillion in annual U.S. drug, device and food sales.
The withdrawal followed demands from Republican senators for written assurances on abortion-related policy before they would vote to confirm her, according to CBS News. Sen. Bill Cassidy of Louisiana, the outgoing chairman of the Senate Health, Education, Labor and Pensions Committee, said the holdup was not about Overton's credentials.
"Pro-life Senators sought final assurances from the Administration regarding the Administration's commitment to life issues," Cassidy said late Tuesday, arguing the White House "abandoned a viable confirmation path."
The collapse leaves the FDA without a Senate-confirmed commissioner at a moment when the agency is weighing major decisions on drug approvals, food safety rules and the regulation of tobacco and nicotine products. An acting commissioner will continue to run the agency in the interim.
Overton, a physician, was nominated to succeed Robert Califf, who led the FDA for most of the Biden administration. The FDA commissioner oversees about 18,000 employees and a budget of more than $7 billion in appropriated funds, and the post has historically drawn bipartisan scrutiny over conflicts between scientific review and political pressure.
Cassidy's committee is the panel that would have handled Overton's confirmation hearing, and his public criticism of the White House's handling of the withdrawal is unusual for a senator of the same party as the president. His statement placed the blame on the administration rather than on the nominee, saying the White House walked away from a path to confirmation rather than working through senators' concerns.
The withdrawal is the latest in a series of stalled or failed nominations to health agencies in recent years. The FDA has operated under acting leadership for extended stretches before, but a prolonged vacancy at the top can slow rulemaking and complicate the agency's dealings with Congress and the industries it regulates.
It was not immediately clear whether the White House would put forward a new nominee or leave an acting commissioner in place. The FDA declined to comment on the withdrawal.